TriLink CleanCap® IVT Kits for mRNA Synthesis

Greater Flexibility for Your Research Workflows, Same Trusted Performance

In mRNA research and development, consistency, yield and workflow efficiency are not optional, they are essential. TriLink® CleanCap® IVT Kits continue to set the benchmark for high-performance in vitro mRNA synthesis, enabling you to generate high-yield, translationally optimised mRNA with consistent capping efficiency and minimal dsRNA by-product. Now, with newly optimised kit sizes, you gain the flexibility to align synthesis capacity precisely with your experimental needs, without changing your chemistry, workflow, or expected performance.

Whether you are:

• Validating a new construct

• Optimising reaction conditions

• Running multiple small-scale experiments

• Scaling up synthesis for advanced studies

The new kit formats allow you to choose the scale that best suits your project,  improving cost-efficiency and workflow planning while maintaining the reliability you depend on.

CleanCap® AG (3′-OMe) CleanScript™ IVT Kit, New Options

These updated formats provide:

• Greater flexibility for pilot studies and optimisation work

• Improved suitability for higher throughput synthesis

• Better alignment with R&D budgeting and project planning

Importantly, there are no changes to the chemistry, performance, or workflow.

Figure 1: Reduced dsRNA formation by CleanScribe RNA Polymerase in synthesis of unmodified or N1MePsU–modified mRNAs with CleanCap AG (3′ OMe) and CleanCap M6 cap analogs.

Performance You Trust

The new formats retain the best-in-class characteristics that researchers rely on:

• Efficient co-transcriptional cap incorporation

• High mRNA yield and integrity

• Low dsRNA impurity profile

• Compatibility with downstream applications including:

  • Transfection

  • In vivo delivery studies

  • mRNA analytics

Seamless Transition, No Protocol Changes Required

Switching from legacy kit formats to the new sizes is straightforward.

• Same trusted capping chemistry

• Same reaction conditions

• Same robust performance

• No protocol modifications required

This ensures uninterrupted workflow continuity while giving you greater flexibility in experimental design.

Supporting Your Research Every Step of the Way

If you would like assistance selecting the most suitable format for your application, or if you have questions regarding the transition, our team is here to help.

"Same Chemistry. Same Performance. Broader Flexibility for Your Research Workflows."

• References

  Article content created by Tebubio using courtesy materials provided by TriLink Biotechnologies.

Need Expert Guidance for Your mRNA Synthesis?

Tebubio’s scientific team can help you choose the right TriLink CleanCap® IVT Kit size for your workflow, from small-scale optimisation to higher-throughput mRNA production—while keeping high yield, consistent capping, and low dsRNA.